Malaria
Prevention and Treatment

Jhpiego supports National Malaria Programs for effective malaria programming and implementation,
Overcoming barriers while strengthening the efficiency of health systems.

Malaria is a deadly disease transmitted to people by mosquitoes. Even though it is both preventable and treatable, it remains one of the most serious global health problems, especially for pregnant women and children. Jhpiego works with governments and local partners in sub-Saharan Africa and Asia to deliver quality malaria prevention, diagnosis and treatment services.

Pregnancy reduces a woman’s immunity to malaria, which makes her more susceptible to malaria infection and increases her risk of severe anemia, miscarriage, stillbirth, premature delivery, delivery of low-birthweight babies and death. Following the birth of a child, the risk of malaria infection and clinical disease increases after the waning of maternal immunity. Children under-five remain susceptible to malaria because they have an immature immune system. Because of this, much of our work focuses on strengthening health service delivery sites at the community and facility level and health workers’ skills to deliver quality prevention, diagnosis, and treatment products and services that significantly reduce illness and death, especially among those most at risk, pregnant women, and children under five.

Our Approaches

Prevention

  • Where there is heavy rain and malaria transmission is seasonal, we advocate for and support the intermittent administration of full treatment courses of an antimalarial medicine by implementing seasonal malaria chemoprevention campaigns. These campaigns are crucial during the malaria season to prevent malaria illness and deaths in children under five years, protecting them throughout the period of greatest malaria risk.

  • We support the prevention of malaria in pregnancy through antenatal care services by providing insecticide-treated nets, including counseling on their use during their first antenatal visit, and by providing intermittent preventive treatment of antimalarial medication during pregnancy to reduce the burden of malaria infection among pregnant women. We implement this support in areas with moderate to high levels of malaria transmission through collaboration with national malaria programs and reproductive and maternal health programs.

  • We educate communities about the importance of the malaria vaccine and collaborate with national malaria and immunization programs to support the decision-making, planning, implementation, and monitoring that goes with introducing and scaling the malaria vaccine alongside other malaria prevention interventions in children.

Diagnosis and treatment

  • We support the strengthening of systems for improving malaria case management by building the capacity of health providers at the community and facility levels and providing them with tools and quality improvement support to promptly test for malaria and appropriately categorize and treat malaria cases.

Program Experts

Dr. Gladys Tetteh

Senior Technical Director for Malaria

Unitaid Awards Jhpiego a Grant to Combat Antimalarial Drug Resistance in Africa

The four-year, $26.5 million grant will help minimize the impact of antimalarial drug resistance.

Pregnant women and children account for the vast majority of deaths due to malaria in Africa.